lymphoid hematological malignancies
Showing 1 - 4 of 4
Relapsed and Refractory, Lymphoid Hematological Malignancies Trial in Hangzhou (GC022F CAR-T cells)
Not yet recruiting
- Relapsed and Refractory
- Lymphoid Hematological Malignancies
- GC022F CAR-T cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Nov 7, 2020
Relapsed and Refractory, Lymphoid Hematological Malignancies Trial in Hangzhou (CD20/CD22 dual Targeted CAR T-cells)
Recruiting
- Relapsed and Refractory
- Lymphoid Hematological Malignancies
- CD20/CD22 dual Targeted CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 20, 2020
Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma Trial in Canada, United States (CB-5083,
Terminated
- Lymphoid Hematological Malignancies
- Relapsed and Refractory Multiple Myeloma
-
Duarte, California
- +7 more
Feb 23, 2018
Lymphoid Hematological Malignancies, Umbilical Cord Blood Transplant Trial (drug, radiation, procedure)
Withdrawn
- Lymphoid Hematological Malignancies
- Umbilical Cord Blood Transplant
- Cytoxan
- +3 more
- (no location specified)
Dec 11, 2013